Navigation Links
Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
Date:5/19/2008

SAN DIEGO, May 19 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of therapeutic oxygen transport agents today announced that it has completed enrollment in the second Phase III trial of its lead product, Hemospan(R).

Sangart expects the top line results from this trial to be available in the second half of 2008.

The 370-patient randomized, double-blind, controlled Phase III study was conducted at 18 clinical sites in six European countries. Together with another Phase III study completed in March, the trials were designed to evaluate the safety and efficacy of Hemospan for preventing and treating hemodynamic instability, particularly hypotension, or low blood pressure, during primary hip replacement surgery.

Dr. Robert Winslow, Chairman, President and CEO of Sangart, commented, "The completed enrollment in this second Phase III trial represents another significant milestone for Sangart as we advance the development of Hemospan."

No similar oxygen transport agents are currently on the market in Europe or the United States. Extensive preclinical efficacy studies and earlier clinical trials indicate that Hemospan's novel oxygen delivery mechanism has the potential to enhance oxygenation of ischemic tissues and may provide a safe and effective alternative to blood transfusion, especially when blood is not immediately available.

About Sangart

Sangart is a privately held San Diego-based biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as therapeutic oxygen transport agents and potential alternatives to blood transfusions.

Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-f
'/>"/>

SOURCE Sangart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
2. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
3. China-Biotics, Inc. Completes Foundation for Its New Plant
4. Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
5. EUSA Pharma Completes Acquisition Of Cytogen Corporation
6. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
7. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
8. Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution
9. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
10. Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections
11. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Va. , March 5, 2015   HX360 ... as semi-finalists in the HX360 Innovation Challenge ... entries, will compete to be chosen as one of ... panel of senior health system executives and venture capitalists ... HX360 Innovation Challenge takes place at the 2015 HIMSS ...
(Date:3/5/2015)... York (PRWEB) March 05, 2015 LifeCell ... to be able to get an Advanced Semen Analysis ... stress, blaming and guessing are all risk factors for ... the woman is the source of the infertility. Infertility ... LifeCell Dx has the simplest, least complicated and ...
(Date:3/5/2015)... 2015 Plant disease specialists from around ... the Annual Meeting of The American Phytopathological Society. ... online now at APSnet.org/meet . , The Preliminary ... to be held August 1-5, 2015 in Pasadena, California, ... Trips, Workshops, and committee meetings, all carefully balanced to ...
(Date:3/5/2015)... Springs, FL (PRWEB) March 05, 2015 ... Damm for the position of Vice President of Managed ... managed care relationships for one of the nation’s leading ... brings more than 15 years of specialty pharmacy and ... Damm worked with Raptor Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. ...
Breaking Biology Technology:HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3American Phytopathological Society Announces Annual Meeting Daily Schedule 2BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2
... 2011 Palatin Technologies, Inc. (NYSE Amex: PTN ... 23rd Annual OC Growth Stock Conference on Tuesday, March 15, ... held at the Ritz Carlton Laguna Niguel in Dana Point, ... Executive Officer of Palatin Technologies, will provide an update on ...
... 2011 AccessClosure, Inc., the U.S. market segment ... from the first published study* (Journal of NeuroInterventional ... different vascular closure devices (VCD) as the primary ... the discomfort associated with the Mynx 5F Vascular ...
... UBM Live and its sister company, UBM Japan ... and new developments taking place at the tenth anniversary of ... 18-20 April, 2011 at the Big Sight Exhibition Center in ... P-MEC Japan, which covers Pharma machinery and equipment, ICSE Japan, ...
Cached Biology Technology:Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 3UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 2UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 3UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 4
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Global Biometrics Market Forecast and Opportunities, 2020" ... market for biometric authentication systems is projected to ... 2020 The driving forces for this ... government projects and constant development in technology. In ...
(Date:3/3/2015)... , March 3, 2015 Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... today announced the expansion of its relationship ... ("Fred Hutch") Clinical Research Division with ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... del Toro Research Station and Galeta Point Marine ... and a major coral bleaching event in the ... Atmospheric Administration, NOAA, issued an advisory in July ... Caribbean region, there had been no clear indication ...
... conference held in Brussels today, the International Osteoporosis Foundation (IOF), ... Group called on health care professionals and health policy officials ... call to action was made at the launch of a ... World Osteoporosis Day on October 20, 2010. Taking ...
... Gardeners could help maintain bumblebee populations by growing plants with ... to field observations of the common snapdragon, Antirrhinum majus ... Bees are important pollinators of crops as well as ... institute of the BBSRC, is committed to research that can ...
Cached Biology News:Smithsonian reports regional sea temperature rise and coral bleaching event in Western Caribbean 2IOF campaign puts spotlight on vastly under-diagnosed and under-treated spinal fractures 2Landing lights for bumblebees 2
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Rabbit polyclonal to ATF4 (phospho S245) ( Abpromise for all tested applications). Antigen: Synthetic phosphopeptide derived from human ATF4 around the phosphorylation site of Serine 245. En...
Evolutionarily conserved signaling intermediate in Toll pathway...
Biology Products: